Details of the Drug

General Information of Drug (ID: DMZMSPF)

Drug Name

Bicalutamide

Synonyms

Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

430.4

Topological Polar Surface Area (xlogp)

2.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is well-absorbed following oral administration [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The apparent oral clearance of drug is 0.32 L/h [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 5.9 days [6]
Metabolism: The drug is metabolized via the glucuronidation [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.93549 micromolar/kg/day [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.005 mg/mL [4]

Chemical Identifiers

Formula: C18H14F4N2O4S
IUPAC Name: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
Canonical SMILES: CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
InChI: InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
InChIKey: LKJPYSCBVHEWIU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2375
ChEBI ID: CHEBI:91617
CAS Number: 90357-06-5
DrugBank ID: DB01128
TTD ID: D0V9BD
VARIDT ID: DR00795
INTEDE ID: DR0210
ACDINA ID: D00069

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[8], [9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Prostate cancer

ICD Disease Classification

2C82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.80E-02	-1.36E-01	-1.05E+00
Breast cancer resistance protein (ABCG2)	DTP	BCRP	1.91E-02	2.50E-01	1.01E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	7.93E-02	-8.20E-02	-8.93E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bicalutamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[46]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[47]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Bicalutamide caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[48]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Idarubicin.	Acute myeloid leukaemia [2A60]	[49]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[49]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Oliceridine.	Acute pain [MG31]	[49]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Ivabradine.	Angina pectoris [BA40]	[49]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Bepridil.	Angina pectoris [BA40]	[50]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Dronedarone.	Angina pectoris [BA40]	[50]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[51]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Bicalutamide caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[52]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Posaconazole.	Aspergillosis [1F20]	[49]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Levalbuterol.	Asthma [CA23]	[53]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Pirbuterol.	Asthma [CA23]	[54]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Bicalutamide caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[55]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[49]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[49]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[49]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[56]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[49]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Retigabine.	Behcet disease [4A62]	[49]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Bicalutamide caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[49]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Bicalutamide and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[57]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Eribulin.	Breast cancer [2C60-2C6Y]	[49]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Bicalutamide caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[58]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Bosutinib.	Breast cancer [2C60-2C6Y]	[49]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[49]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[54]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[53]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[54]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[54]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Halothane.	Corneal disease [9A76-9A78]	[49]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Probucol.	Coronary atherosclerosis [BA80]	[49]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Pasireotide.	Cushing syndrome [5A70]	[50]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Osilodrostat.	Cushing syndrome [5A70]	[49]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Bicalutamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[59]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Clomipramine.	Depression [6A70-6A7Z]	[49]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Doxepin.	Depression [6A70-6A7Z]	[49]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Bicalutamide caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[60]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[49]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Deutetrabenazine.	Dystonic disorder [8A02]	[49]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Ingrezza.	Dystonic disorder [8A02]	[49]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Bicalutamide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[49]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Cannabidiol.	Epileptic encephalopathy [8A62]	[49]
Solifenacin	DMG592Q	Moderate	Decreased metabolism of Bicalutamide caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[61]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Bicalutamide caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[62]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Bicalutamide caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[46]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[49]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Bicalutamide caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[49]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[63]
MK-1439	DM215WE	Minor	Decreased metabolism of Bicalutamide caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Maraviroc	DMTL94F	Moderate	Decreased metabolism of Bicalutamide caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Bicalutamide and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[67]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Bicalutamide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[50]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Bicalutamide caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[68]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Bicalutamide caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[69]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Bicalutamide caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[46]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Bicalutamide caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[70]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Bicalutamide caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[71]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[49]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[50]
Naloxegol	DML0B41	Minor	Decreased metabolism of Bicalutamide caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[72]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Bicalutamide caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[49]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Crizotinib.	Lung cancer [2C25]	[73]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of Bicalutamide caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[46]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Ceritinib.	Lung cancer [2C25]	[50]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Bicalutamide caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[74]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Bicalutamide caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[75]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Osimertinib.	Lung cancer [2C25]	[76]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Bicalutamide caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[77]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Selpercatinib.	Lung cancer [2C25]	[49]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Lumefantrine.	Malaria [1F40-1F45]	[46]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Halofantrine.	Malaria [1F40-1F45]	[78]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[49]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[49]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[79]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Idelalisib.	Mature B-cell leukaemia [2A82]	[80]
GDC-0199	DMH0QKA	Moderate	Decreased metabolism of Bicalutamide caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[46]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[81]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Bicalutamide caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[82]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Vemurafenib.	Melanoma [2C30]	[50]
Selumetinib	DMC7W6R	Moderate	Decreased metabolism of Bicalutamide caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[83]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and LGX818.	Melanoma [2C30]	[49]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Bicalutamide caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[84]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Bicalutamide caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[85]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Siponimod.	Multiple sclerosis [8A40]	[46]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Fingolimod.	Multiple sclerosis [8A40]	[50]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Ozanimod.	Multiple sclerosis [8A40]	[86]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Romidepsin.	Mycosis fungoides [2B01]	[49]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[50]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Bicalutamide caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[49]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[49]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Bicalutamide caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[87]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Bicalutamide caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[88]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lofexidine.	Opioid use disorder [6C43]	[49]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Rucaparib.	Ovarian cancer [2C73]	[49]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Triclabendazole.	Parasitic worm infestation [1F90]	[49]
Pimavanserin	DMR7IVC	Moderate	Decreased metabolism of Bicalutamide caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[89]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[90]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Lefamulin.	Pneumonia [CA40]	[91]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Bicalutamide caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[92]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Bicalutamide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[93]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Bicalutamide caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[94]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Bicalutamide caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[95]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Bicalutamide caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[49]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Bicalutamide caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[96]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Bicalutamide caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[46]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Iloperidone.	Schizophrenia [6A20]	[50]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Paliperidone.	Schizophrenia [6A20]	[49]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Amisulpride.	Schizophrenia [6A20]	[97]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Asenapine.	Schizophrenia [6A20]	[49]
LDE225	DMM9F25	Moderate	Decreased metabolism of Bicalutamide caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[98]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Bicalutamide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[46]
Docetaxel	DMDI269	Moderate	Decreased metabolism of Bicalutamide caused by Docetaxel mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[99]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[49]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[50]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[50]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Bicalutamide caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[100]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Pitolisant.	Somnolence [MG42]	[49]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[49]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Bicalutamide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[101]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lenvatinib.	Thyroid cancer [2D10]	[49]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Cabozantinib.	Thyroid cancer [2D10]	[49]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Bicalutamide caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[49]
Elagolix	DMB2C0E	Moderate	Decreased metabolism of Bicalutamide caused by Elagolix mediated inhibition of CYP450 enzyme.	Uterine fibroid [2E86]	[102]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[49]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[49]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[49]
-----------


⏷ Show the Full List of 132 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 300	E00651	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bicalutamide 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2863).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
9	Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
10	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
11	Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
22	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
23	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
24	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
25	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
26	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
27	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
28	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
29	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
30	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
31	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
32	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
33	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
34	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
35	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
36	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
37	Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
38	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
39	Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
40	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
41	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
42	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
43	CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
44	Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
45	An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
46	Cerner Multum, Inc. "Australian Product Information.".
47	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
48	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
49	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
50	Canadian Pharmacists Association.
51	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
52	Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
53	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
54	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
55	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
56	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
57	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
58	Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
59	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
60	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
61	Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
62	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
63	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
64	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
65	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
66	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
67	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
68	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
69	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
70	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
71	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
72	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
73	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
75	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
76	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
78	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
79	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
80	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
81	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
82	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
83	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
84	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
85	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
86	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
87	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
88	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
89	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
90	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
91	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
92	Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
93	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
94	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
95	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
96	Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
97	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
98	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
99	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
100	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
101	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
102	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.